Working closely with the Hemanext team, we crafted medical animations to elucidate the science behind oxidative damage in stored blood. To leverage the visuals for multiple communication needs, the content was broken into chapters.
This editorial image was created for Roche’s pRED to describe their Brain Shuttle technology. The illustration describes the maze-like challenges of delivering an antibody therapeutic across the blood-brain barrier. View our “Brain Shuttle” animation to learn more about the blood-brain barrier and the mechanism of action of Roche’s novel Roche Brain shuttle engineering platform.
This editorial image was created to describe the challenges of delivering an antibody therapeutic across the blood-brain barrier.
Sonnet BioTherapeutics requested an animation to help explain how their Fully Human Albumin Binding (FHAB) platform functions and the potential benefits of the platform over existing anti-tumor therapies. With vivid colors and key lighting details, the FHAB is clearly the star of the show in this animation.
X4 Pharmaceuticals wanted to create a 3D medical animation for the launch of their therapeutic XOLREMDI, indicated for the treatment of WHIM syndrome, a rare immunodeficiency disorder. The main goal was to communicate the complexity of WHIM syndrome and how XOLREMDI cuts through this complexity by targeting the underlying cause of the disease.
Shattuck Labs enlisted XVIVO to develop a mechanism of action animation for their ARC platform (or Agonist Redirected Checkpoint), which links checkpoint blockade and immune co-stimulation in a single molecule, to treat cancer.
XVIVO recently partnered with Werewolf Therapeutics to create an animation about their INDUKINE molecules and how the molecules could transform immunotherapy as it is practiced today. Werewolf leadership had worked with XVIVO on a previous animation and really enjoyed the process and the final product. So it was an easy decision to pick a scientific animation studio when Werewolf needed help visualizing their science.
XVIVO and Forma partnered together for multiple medical animation projects to educate both healthcare professionals and patients on their scientific approach. Sickle cell disease is an inherited genetic disease that has serious impacts on the people living with it. Forma Therapeutics is fiercely dedicated to improving the lives of these patients.
Iconic Therapeutics requested 3 illustrations depicting the structure and function of tissue factor in the human body and disease.